FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155012968> ?p ?o ?g. }

• W2155012968 endingPage "5428" @default.
• W2155012968 startingPage "5422" @default.
• W2155012968 abstract "Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A prospective, randomized phase III trial of bevacizumab plus IFN versus IFN monotherapy was conducted.Patients with previously untreated, metastatic clear-cell RCC were randomly assigned to receive either bevacizumab (10 mg/kg intravenously every 2 weeks) plus IFN (9 million U subcutaneously three times weekly) or the same dose and schedule of IFN monotherapy in a multicenter phase III trial. The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS), objective response rate (ORR), and safety.Between October 2003 and July 2005, 732 patients were enrolled. The prespecified stopping rule for OS has not yet been reached. The median PFS was 8.5 months in patients receiving bevacizumab plus IFN (95% CI, 7.5 to 9.7 months) versus 5.2 months (95% CI, 3.1 to 5.6 months) in patients receiving IFN monotherapy (log-rank P < .0001). The adjusted hazard ratio was 0.71 (95% CI, 0.61 to 0.83; P < .0001). Bevacizumab plus IFN had a higher ORR as compared with IFN (25.5% [95% CI, 20.9% to 30.6%] v 13.1% [95% CI, 9.5% to 17.3%]; P < .0001). Overall toxicity was greater for bevacizumab plus IFN, including significantly more grade 3 hypertension (9% v 0%), anorexia (17% v 8%), fatigue (35% v 28%), and proteinuria (13% v 0%).Bevacizumab plus IFN produces a superior PFS and ORR in untreated patients with metastatic RCC as compared with IFN monotherapy. Toxicity is greater in the combination therapy arm." @default.
• W2155012968 created "2016-06-24" @default.
• W2155012968 creator A5007578304 @default.
• W2155012968 creator A5017353925 @default.
• W2155012968 creator A5025529463 @default.
• W2155012968 creator A5033346506 @default.
• W2155012968 creator A5034354367 @default.
• W2155012968 creator A5035975628 @default.
• W2155012968 creator A5045207535 @default.
• W2155012968 creator A5050435057 @default.
• W2155012968 creator A5053535513 @default.
• W2155012968 creator A5068100232 @default.
• W2155012968 creator A5075361066 @default.
• W2155012968 creator A5088131964 @default.
• W2155012968 date "2008-11-20" @default.
• W2155012968 modified "2023-10-01" @default.
• W2155012968 title "Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206" @default.
• W2155012968 cites W1497429764 @default.
• W2155012968 cites W1514961004 @default.
• W2155012968 cites W1666874820 @default.
• W2155012968 cites W1857696541 @default.
• W2155012968 cites W1880480189 @default.
• W2155012968 cites W1928193662 @default.
• W2155012968 cites W1999966467 @default.
• W2155012968 cites W2010160635 @default.
• W2155012968 cites W2046507292 @default.
• W2155012968 cites W2076424556 @default.
• W2155012968 cites W2098136315 @default.
• W2155012968 cites W2100669312 @default.
• W2155012968 cites W2101047730 @default.
• W2155012968 cites W2104540972 @default.
• W2155012968 cites W2139248078 @default.
• W2155012968 cites W2143782771 @default.
• W2155012968 cites W2149456801 @default.
• W2155012968 cites W2150162153 @default.
• W2155012968 cites W2171469612 @default.
• W2155012968 cites W2268972797 @default.
• W2155012968 cites W2301603902 @default.
• W2155012968 cites W2334694951 @default.
• W2155012968 cites W2610313261 @default.
• W2155012968 cites W2887131627 @default.
• W2155012968 cites W3147894994 @default.
• W2155012968 cites W4293241248 @default.
• W2155012968 cites W4298379398 @default.
• W2155012968 doi "https://doi.org/10.1200/jco.2008.16.9847" @default.
• W2155012968 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2651074" @default.
• W2155012968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18936475" @default.
• W2155012968 hasPublicationYear "2008" @default.
• W2155012968 type Work @default.
• W2155012968 sameAs 2155012968 @default.
• W2155012968 citedByCount "842" @default.
• W2155012968 countsByYear W21550129682012 @default.
• W2155012968 countsByYear W21550129682013 @default.
• W2155012968 countsByYear W21550129682014 @default.
• W2155012968 countsByYear W21550129682015 @default.
• W2155012968 countsByYear W21550129682016 @default.
• W2155012968 countsByYear W21550129682017 @default.
• W2155012968 countsByYear W21550129682018 @default.
• W2155012968 countsByYear W21550129682019 @default.
• W2155012968 countsByYear W21550129682020 @default.
• W2155012968 countsByYear W21550129682021 @default.
• W2155012968 countsByYear W21550129682022 @default.
• W2155012968 countsByYear W21550129682023 @default.
• W2155012968 crossrefType "journal-article" @default.
• W2155012968 hasAuthorship W2155012968A5007578304 @default.
• W2155012968 hasAuthorship W2155012968A5017353925 @default.
• W2155012968 hasAuthorship W2155012968A5025529463 @default.
• W2155012968 hasAuthorship W2155012968A5033346506 @default.
• W2155012968 hasAuthorship W2155012968A5034354367 @default.
• W2155012968 hasAuthorship W2155012968A5035975628 @default.
• W2155012968 hasAuthorship W2155012968A5045207535 @default.
• W2155012968 hasAuthorship W2155012968A5050435057 @default.
• W2155012968 hasAuthorship W2155012968A5053535513 @default.
• W2155012968 hasAuthorship W2155012968A5068100232 @default.
• W2155012968 hasAuthorship W2155012968A5075361066 @default.
• W2155012968 hasAuthorship W2155012968A5088131964 @default.
• W2155012968 hasBestOaLocation W21550129681 @default.
• W2155012968 hasConcept C126322002 @default.
• W2155012968 hasConcept C141071460 @default.
• W2155012968 hasConcept C143998085 @default.
• W2155012968 hasConcept C168563851 @default.
• W2155012968 hasConcept C203092338 @default.
• W2155012968 hasConcept C207103383 @default.
• W2155012968 hasConcept C2776694085 @default.
• W2155012968 hasConcept C2777472916 @default.
• W2155012968 hasConcept C2777802072 @default.
• W2155012968 hasConcept C2779561371 @default.
• W2155012968 hasConcept C2780091579 @default.
• W2155012968 hasConcept C44249647 @default.
• W2155012968 hasConcept C71924100 @default.
• W2155012968 hasConcept C90924648 @default.
• W2155012968 hasConceptScore W2155012968C126322002 @default.
• W2155012968 hasConceptScore W2155012968C141071460 @default.
• W2155012968 hasConceptScore W2155012968C143998085 @default.
• W2155012968 hasConceptScore W2155012968C168563851 @default.
• W2155012968 hasConceptScore W2155012968C203092338 @default.
• W2155012968 hasConceptScore W2155012968C207103383 @default.
• W2155012968 hasConceptScore W2155012968C2776694085 @default.

• next